These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 35292162)

  • 41. COVID-19 vaccine hesitancy in Zambia: a glimpse at the possible challenges ahead for COVID-19 vaccination rollout in sub-Saharan Africa.
    Carcelen AC; Prosperi C; Mutembo S; Chongwe G; Mwansa FD; Ndubani P; Simulundu E; Chilumba I; Musukwa G; Thuma P; Kapungu K; Hamahuwa M; Mutale I; Winter A; Moss WJ; Truelove SA
    Hum Vaccin Immunother; 2022 Dec; 18(1):1-6. PubMed ID: 34227914
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial.
    Kremsner PG; Ahuad Guerrero RA; Arana-Arri E; Aroca Martinez GJ; Bonten M; Chandler R; Corral G; De Block EJL; Ecker L; Gabor JJ; Garcia Lopez CA; Gonzales L; Granados González MA; Gorini N; Grobusch MP; Hrabar AD; Junker H; Kimura A; Lanata CF; Lehmann C; Leroux-Roels I; Mann P; Martinez-Reséndez MF; Ochoa TJ; Poy CA; Reyes Fentanes MJ; Rivera Mejia LM; Ruiz Herrera VV; Sáez-Llorens X; Schönborn-Kellenberger O; Schunk M; Sierra Garcia A; Vergara I; Verstraeten T; Vico M; Oostvogels L;
    Lancet Infect Dis; 2022 Mar; 22(3):329-340. PubMed ID: 34826381
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Insights into COVID-19 Vaccine Development Based on Immunogenic Structural Proteins of SARS-CoV-2, Host Immune Responses, and Herd Immunity.
    Chaudhary JK; Yadav R; Chaudhary PK; Maurya A; Kant N; Rugaie OA; Haokip HR; Yadav D; Roshan R; Prasad R; Chatrath A; Singh D; Jain N; Dhamija P
    Cells; 2021 Oct; 10(11):. PubMed ID: 34831172
    [TBL] [Abstract][Full Text] [Related]  

  • 44. mRNA vaccines for COVID-19: what, why and how.
    Park JW; Lagniton PNP; Liu Y; Xu RH
    Int J Biol Sci; 2021; 17(6):1446-1460. PubMed ID: 33907508
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Current advances in the development of SARS-CoV-2 vaccines.
    Awadasseid A; Wu Y; Tanaka Y; Zhang W
    Int J Biol Sci; 2021; 17(1):8-19. PubMed ID: 33390829
    [TBL] [Abstract][Full Text] [Related]  

  • 46. COVID-19 Vaccination in Children: An Open Question.
    Campagnani G; Bardanzellu F; Pintus MC; Fanos V; Marcialis MA
    Curr Pediatr Rev; 2022; 18(3):226-236. PubMed ID: 34931965
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Aggregating Human Judgment Probabilistic Predictions of Coronavirus Disease 2019 Transmission, Burden, and Preventive Measures.
    Codi A; Luk D; Braun D; Cambeiro J; Besiroglu T; Chen E; de Cesaris LEU; Bocchini P; McAndrew T
    Open Forum Infect Dis; 2022 Aug; 9(8):ofac354. PubMed ID: 35937647
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A comparative analysis on the safety and efficacy of Covaxin versus other vaccines against COVID-19: a review.
    Talukder A; Kalita C; Neog N; Goswami C; Sarma MK; Hazarika I
    Z Naturforsch C J Biosci; 2022 Jul; 77(7-8):351-362. PubMed ID: 35245422
    [TBL] [Abstract][Full Text] [Related]  

  • 49. SARS-CoV-2 vaccines for cancer patients: a call to action.
    Corti C; Crimini E; Tarantino P; Pravettoni G; Eggermont AMM; Delaloge S; Curigliano G
    Eur J Cancer; 2021 May; 148():316-327. PubMed ID: 33770576
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Third Wave of the COVID-19 Pandemic: Prominence of Initial Public Health Interference.
    Mukherjee S; Ray SK
    Infect Disord Drug Targets; 2022; 22(4):e080222200919. PubMed ID: 35135456
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Social network-based ethical analysis of COVID-19 vaccine supply policy in three Central Asian countries.
    Aripov T; Wikler D; Asadov D; Tulekov Z; Murzabekova T; Munir KM
    BMC Med Ethics; 2022 Mar; 23(1):21. PubMed ID: 35264173
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Misrepresentation about vaccines that are scaring women.
    Moodley J; Khaliq OP; Mkhize PZ
    Afr J Prim Health Care Fam Med; 2021 Jun; 13(1):e1-e2. PubMed ID: 34212737
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem.
    Conti P; Caraffa A; Gallenga CE; Kritas SK; Frydas I; Younes A; Di Emidio P; Tetè G; Pregliasco F; Ronconi G
    J Biol Regul Homeost Agents; 2021; 35(1):1-4. PubMed ID: 33377359
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Humoral and Cellular Immunogenicity and Safety of Five Different SARS-CoV-2 Vaccines in Patients With Autoimmune Rheumatic and Musculoskeletal Diseases in Remission or With Low Disease Activity and in Healthy Controls: A Single Center Study.
    Szebeni GJ; Gémes N; Honfi D; Szabó E; Neuperger P; Balog JÁ; Nagy LI; Szekanecz Z; Puskás LG; Toldi G; Balog A
    Front Immunol; 2022; 13():846248. PubMed ID: 35432314
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The race for a COVID-19 vaccine: where are we up to?
    Hossain MK; Hassanzadeganroudsari M; Feehan J; Apostolopoulos V
    Expert Rev Vaccines; 2022 Mar; 21(3):355-376. PubMed ID: 34937492
    [TBL] [Abstract][Full Text] [Related]  

  • 56. An update on the impact of SARS-CoV-2 pandemic public awareness on cancer patients' COVID-19 vaccine compliance: Outcomes and recommendations.
    Souan L; Sughayer MA; Abu Alhowr M; Ammar K; Bader SA
    Front Public Health; 2022; 10():923815. PubMed ID: 35937267
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Efficacy of the adjuvanted subunit protein COVID-19 vaccine, SCB-2019: a phase 2 and 3 multicentre, double-blind, randomised, placebo-controlled trial.
    Bravo L; Smolenov I; Han HH; Li P; Hosain R; Rockhold F; Clemens SAC; Roa C; Borja-Tabora C; Quinsaat A; Lopez P; López-Medina E; Brochado L; Hernández EA; Reynales H; Medina T; Velasquez H; Toloza LB; Rodriguez EJ; de Salazar DIM; Rodríguez CA; Sprinz E; Cerbino-Neto J; Luz KG; Schwarzbold AV; Paiva MS; Carlos J; Montellano MEB; de Los Reyes MRA; Yu CY; Alberto ER; Panaligan MM; Salvani-Bautista M; Buntinx E; Hites M; Martinot JB; Bhorat QE; Badat A; Baccarini C; Hu B; Jurgens J; Engelbrecht J; Ambrosino D; Richmond P; Siber G; Liang J; Clemens R
    Lancet; 2022 Jan; 399(10323):461-472. PubMed ID: 35065705
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Vaccination against SARS-CoV-2 and disease enhancement - knowns and unknowns.
    Zellweger RM; Wartel TA; Marks F; Song M; Kim JH
    Expert Rev Vaccines; 2020 Aug; 19(8):691-698. PubMed ID: 32838605
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Vaccination contre le SARS-CoV-2, le Graal ?].
    Binh Luong Nguyen L; Lachâtre M; Launay O
    Rev Prat; 2022 May; 72(5):517-522. PubMed ID: 35899638
    [TBL] [Abstract][Full Text] [Related]  

  • 60. mRNA Vaccine: How to Meet the Challenge of SARS-CoV-2.
    Jin Y; Hou C; Li Y; Zheng K; Wang C
    Front Immunol; 2021; 12():821538. PubMed ID: 35126377
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.